Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genotype-based therapeutic approach for colorectal cancer: state of the art and future perspectives.

Expert opinion on pharmacotherapy - 1 May 2009

Fogli Stefano, Caraglia Michele

Abstract excerpt

BACKGROUND: There is a considerable need to increase efforts in maximizing clinical outcome in the treatment of colorectal cancer, and the identification of genetic factors underlying drug response seems to be one of the most promising areas in this research field. METHODS: Clinical trials and pharmacogenetic association studies were reviewed to offer an overview of the most commonly reported polymorphisms in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Neoplasms
Share to Genotype
Share to Pharmacogenetics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19405786
DOI: 10.1517/14656560902889775

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotype-based therapeutic approach for colorectal cancer: state of the art and future perspectives.PMID 19405786Read ↗

Pharmacogenomics in colorectal cancer: The first step for individualized-therapySemantic proximity Read ↗

Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer.Semantic proximity Read ↗

Genetic determinants of cancer drug efficacy and toxicity: practical considerations and perspectives.Semantic proximity Read ↗

Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.Semantic proximity Read ↗

Pharmacogenetics of Anticancer Drug Sensitivity and Toxicity in Colorectal Cancer.Semantic proximity Read ↗

<i>Thymidylate synthase</i>gene variations: predictive and prognostic markersSemantic proximity Read ↗

Genetic polymorphisms and tumoral mutational profile over survival in advanced colorectal cancer patients: an exploratory studySemantic proximity Read ↗

Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review).Semantic proximity Read ↗

The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer.Semantic proximity Read ↗

Update on pharmacogenetics in cancer chemotherapy.Semantic proximity Read ↗

Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer.Semantic proximity Read ↗

UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.